• Principal Investigator
  • Male

Prof. dr. R. Versteeg

Position:
Main activities: Research
Specialisation:
foto R. Versteeg is one of the AMC Principal Investigators
Focus of research:

Focus of research are firstly the molecular biology and genetic defects of several pediatric tumors (neuroblastoma, medulloblastoma and rhabdomyosarcoma) and secondly the overall organization of gene expression of the human genome. Both research lines are supported by a strong bioinformatics and systems biology approach. The pediatric oncology research ranges from analysis of patient material for prognostic research, via fundamental research on molecular pathways and pathologic mechanisms, to validation of targets for novel drugs. In general, we search for genes mutated in tumors of pediatric cancer patients and subsequently try to reconstruct the molecular pathways in which these genes function. This is done by inducible expression of transgenes in cell lines, followed by mRNA profiling using microarrays or SAGE. Expression constructs include dominant negative genes and siRNA constructs. In parallel, large tumor series are analyzed by microarrays. Bioinformatic approaches and further wet-lab approaches are used to reconstruct the molecular pathways and their complex interactions. Pathways studied include the cell cycle, the N-myc and Delta-Notch pathways and pathways of many homeobox proteins like Meis1, Phox2B, Msx1 and Otx1. RNA interference is used to validate components of these pathways for suitatable drug targets, or to validate available and experimental drugs, both in cell lines and mice. The data from all high trouhput mRNA analyses and the bioinformatic tools developed to analyse them, are also used in the project to analyse the expression profile of the human genome. In this program we analyze the mechanisms and principles underlying our observation that the human genome is subdivided in domains of high and low gene expression.

AMC themes: Oncology
Departments: Oncogenomics, Paediatrics: Oncology
Bate-Eya LT, Gierman HJ, Ebus ME, Koster J, Caron HN, Versteeg R, Dolman MEM, Molenaar JJ, Enhancer of zeste homologue 2 plays an important role in neuroblastoma cell survival independent of its histone methyltransferase activity. EUR J CANCER 2017;75:63-72 [PubMed]
van Groningen T , Koster J, Valentijn LJ, Zwijnenburg DA, Akogul N , Hasselt NE, Broekmans M, Haneveld F, Nowakowska NE, Bras J, van Noesel CJM, Jongejan A, van Kampen AH, Koster L, Baas F, van Dijk-Kerkhoven L, Huizer-Smit M, Lecca MC, Chan A, Lakeman A, Molenaar P, Volckmann R, Westerhout EM, Hamdi M, van Sluis PG, Ebus ME, Molenaar JJ, Tytgat GA, Westerman BA, van Nes J, Versteeg R, Neuroblastoma is composed of two super-enhancer-associated differentiation states. NAT GENET 2017;49 (8):1261-1266 [PubMed]
Bate-Eya LT, den Hartog IJM, van der Ploeg I, Schild L, Koster J, Santo EE, Westerhout EM, Versteeg R, Caron HN, Molenaar JJ, Dolman MEM, High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition. ONCOTARGET 2016;7 (19):27946-27958 [PubMed]
Fabian J, Opitz D, Althoff K, Lodrini M, Hero B, Volland R, Beckers A, de Preter K, Decock A, Patil N, Abba M, Kopp-Schneider A, Astrahantseff K, Wünschel J, Pfeil S, Ercu M, Künkele A, Hu J, Thole T, Schweizer L, Mechtersheimer G, Carter D, Cheung BB, Popanda O, Deimling AV, Koster J, Versteeg R, Schwab M, Marshall GM, Speleman F, Erb U, Zoeller M, Allgayer H, Simon T, Fischer M, Kulozik AE, Eggert A, Witt O, Schulte JH, Deubzer HE, MYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastoma. ONCOTARGET 2016;7 (41):66344-66359 [PubMed]
Johann PD, Erkek S, Zapatka M, Kerl K, Buchhalter I, Hovestadt V, Jones DTW, Sturm D, Hermann C, Segura Wang M, Korshunov A, Rhyzova M, Gröbner S, Brabetz S, Chavez L, Bens S, Gröschel S, Kratochwil F, Wittmann A, Sieber L, Geörg C, Wolf S, Beck K, Oyen F, Capper D, van Sluis P, Volckmann R, Koster J, Versteeg R, von Deimling A, Milde T, Witt O, Kulozik AE, Ebinger M, Shalaby T, Grotzer M, Sumerauer D, Zamecnik J, Mora J, Jabado N, Taylor MD, Huang A, Aronica E, Bertoni A, Radlwimmer B, Pietsch T, Schüller U, Schneppenheim R, Northcott PA, Korbel JO, Siebert R, Frühwald MC, Lichter P, Eils R, Gajjar A, Hasselblatt M, Pfister SM, Kool M, Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes. CANCER CELL 2016;29 (3):379-393 [PubMed]
Matas-Rico E, van Veen M, Leyton-Puig D, van den Berg J, Koster J, Kedziora KM, Molenaar B, Weerts MJA, de Rink I, Medema RH, Giepmans BNG, Perrakis A, Jalink K, Versteeg R, Moolenaar WH, Glycerophosphodiesterase GDE2 Promotes Neuroblastoma Differentiation through Glypican Release and Is a Marker of Clinical Outcome. CANCER CELL 2016;30 (4):548-562 [PubMed]
Matas-Rico E, van Veen M, Leyton-Puig D, van den Berg J, Koster J, Kedziora KM, Molenaar B, Weerts MJA, de Rink I, Medema RH, Giepmans BNG, Perrakis A, Jalink K, Versteeg R, Moolenaar WH, Glycerophosphodiesterase GDE2 Promotes Neuroblastoma Differentiation through Glypican Release and Is a Marker of Clinical Outcome (vol 30, pg 548, 2016). CANCER CELL 2016;30 (6):986 [PubMed]
Sturm D, Orr BA, Toprak UH, Hovestadt V, Jones DTW, Capper D, Sill M, Buchhalter I, Northcott PA, Leis I, Ryzhova M, Koelsche C, Pfaff E, Allen SJ, Balasubramanian G, Worst BC, Pajtler KW, Brabetz S, Johann PD, Sahm F, Reimand J, Mackay A, Carvalho DM, Remke M, Phillips JJ, Perry A, Cowdrey C, Drissi R, Fouladi M, Giangaspero F, Łastowska M, Grajkowska W, Scheurlen W, Pietsch T, Hagel C, Gojo J, Lötsch D, Berger W, Slavc I, Haberler C, Jouvet A, Holm S, Hofer S, Prinz M, Keohane C, Fried I, Mawrin C, Scheie D, Mobley BC, Schniederjan MJ, Santi M, Buccoliero AM, Dahiya S, Kramm CM, von Bueren AO, von Hoff K, Rutkowski S, Herold-Mende C, Frühwald MC, Milde T, Hasselblatt M, Wesseling P, Rößler J, Schüller U, Ebinger M, Schittenhelm J, Frank S, Grobholz R, Vajtai I, Hans V, Schneppenheim R, Zitterbart K, Collins VP, Aronica E, Varlet P, Puget S, Dufour C, Grill J, Figarella-Branger D, Wolter M, Schuhmann MU, Shalaby T, Grotzer M, van Meter T, Monoranu CM, Felsberg J, Reifenberger G, Snuderl M, Forrester LA, Koster J, Versteeg R, Volckmann R, van Sluis P, Wolf S, Mikkelsen T, Gajjar A, Aldape K, Moore AS, Taylor MD, Jones C, Jabado N, Karajannis MA, Eils R, Schlesner M, Lichter P, von Deimling A, Pfister SM, Ellison DW, Korshunov A, Kool M, New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. CELL 2016;164 (5):1060-1072 [PubMed]
Vella S, Tavanti E, Hattinger CM, Fanelli M, Versteeg R, Koster J, Picci P, Serra M, Targeting CDKs with Roscovitine Increases Sensitivity to DNA Damaging Drugs of Human Osteosarcoma Cells. PLOS ONE 2016;11 (11):e0166233 [PubMed]
Versteeg R, George RE, Targeting ALK: The Ten Lives of a Tumor. CANCER DISCOV 2016;6 (1):20-21 [PubMed]
Bleeker G, van Eck-Smit BL, Zwinderman KH, Versteeg R, van Noesel MM, Kam BL, Kaspers GJ, van Schie A, Kreissman SG, Yanik G, Hero B, Schmidt M, Laureys G, Lambert B, Øra I, Schulte JH, Caron HN, Tytgat GA, MIBG scans in patients with stage 4 neuroblastoma reveal two metastatic patterns, one is associated with MYCN amplification and in MYCN-amplified tumours correlates with a better prognosis. EUR J NUCL MED MOL I 2015;42 (2):222-230 [PubMed]
Dolman MEM, Poon E, Ebus ME, den Hartog IJM, van Noesel CJM, Jamin Y, Hallsworth A, Robinson SP, Petrie K, Sparidans RW, Kok RJ, Versteeg R, Caron HN, Chesler L, Molenaar JJ, Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma. CLIN CANCER RES 2015;21 (22):5100-5109 [PubMed]
Dolman MEM, van der Ploeg I, Koster J, Bate-Eya LT, Versteeg R, Caron HN, Molenaar JJ, DNA-Dependent Protein Kinase As Molecular Target for Radiosensitization of Neuroblastoma Cells. PLOS ONE 2015;10 (12):e0145744 [PubMed]
Eleveld TF, Oldridge DA, Bernard V, Koster J, Daage LC, Diskin SJ, Schild L, Bentahar NB, Bellini A, Chicard M, Lapouble E, Combaret V, Legoix-Né P, Michon J, Pugh TJ, Hart LS, Rader J, Attiyeh EF, Wei JS, Zhang S, Naranjo A, Gastier-Foster JM, Hogarty MD, Asgharzadeh S, Smith MA, Guidry Auvil JM, Watkins TBK, Zwijnenburg DA, Ebus ME, van Sluis P, Hakkert A, van Wezel E, van der Schoot CE, Westerhout EM, Schulte JH, Tytgat GA, Dolman MEM, Janoueix-Lerosey I, Gerhard DS, Caron HN, Delattre O, Khan J, Versteeg R, Schleiermacher G, Molenaar JJ, Maris JM, Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. NAT GENET 2015;47 (8):864-871 [PubMed]
Mandriota SJ, Valentijn LJ, Lesne L, Betts DR, Marino D, Boudal-Khoshbeen M, London WB, Rougemont AL, Attiyeh EF, Maris JM, Hogarty MD, Koster J, Molenaar JJ, Versteeg R, Ansari M, Gumy-Pause F, Ataxia-telangiectasia mutated (ATM) silencing promotes neuroblastoma progression through a MYCN independent mechanism. ONCOTARGET 2015;6 (21):18558-18576 [PubMed]
Mengelbier LH, Karlsson J, Lindgren D, Valind A, Lilljebjörn H, Jansson C, Bexell D, Braekeveldt N, Ameur A, Jonson T, Kultima HG, Isaksson A, Asmundsson J, Versteeg R, Rissler M, Fioretos T, Sandstedt B, Börjesson A, Backman T, Pal N, Øra I, Mayrhofer M, Gisselsson D, Intratumoral genome diversity parallels progression and predicts outcome in pediatric cancer. NAT COMMUN 2015;6:6125 [PubMed]
Pajtler KW, Witt H, Sill M, Jones DTW, Hovestadt V, Kratochwil F, Wani K, Tatevossian R, Punchihewa C, Johann P, Reimand J, Warnatz HJ, Ryzhova M, Mack S, Ramaswamy V, Capper D, Schweizer L, Sieber L, Wittmann A, Huang Z, van Sluis P, Volckmann R, Koster J, Versteeg R, Fults D, Toledano H, Avigad S, Hoffman LM, Donson AM, Foreman N, Hewer E, Zitterbart K, Gilbert M, Armstrong TS, Gupta N, Allen JC, Karajannis MA, Zagzag D, Hasselblatt M, Kulozik AE, Witt O, Collins VP, von Hoff K, Rutkowski S, Pietsch T, Bader G, Yaspo ML, von Deimling A, Lichter P, Taylor MD, Gilbertson R, Ellison DW, Aldape K, Korshunov A, Kool M, Pfister SM, Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. CANCER CELL 2015;27 (5):728-743 [PubMed]
Santo EE. Forkheads in neuroblastoma & human longevity: From the womb to the tomb. S.l.: s.n.; 2015. 222p. [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Versteeg R; copromotor(s): Westerhout EM)
Valentijn LJ, Koster J, Zwijnenburg DA, Hasselt NE, van Sluis P, Volckmann R, van Noesel MM, George RE, Tytgat GAM, Molenaar JJ, Versteeg R, TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors. NAT GENET 2015;47 (12):1411-+ [PubMed]
van de Wetering M, Francies HE, Francis JM, Bounova G, Iorio F, Pronk A, van Houdt W, van Gorp J, Taylor-Weiner A, Kester L, McLaren-Douglas A, Blokker J, Jaksani S, Bartfeld S, Volckman R, van Sluis P, Li VSW, Seepo S, Sekhar Pedamallu C, Cibulskis K, Carter SL, McKenna A, Lawrence MS, Lichtenstein L, Stewart C, Koster J, Versteeg R, van Oudenaarden A, Saez-Rodriguez J, Vries RGJ, Getz G, Wessels L, Stratton MR, McDermott U, Meyerson M, Garnett MJ, Clevers H, Prospective derivation of a living organoid biobank of colorectal cancer patients. CELL 2015;161 (4):933-945 [PubMed]
van Wezel EM, Zwijnenburg D, Zappeij-Kannegieter L, Bus E, van Noesel MM, Molenaar JJ, Versteeg R, Fiocco M, Caron HN, van der Schoot CE, Koster J, Tytgat GAM, Whole-genome sequencing identifies patient-specific DNA minimal residual disease markers in neuroblastoma. J MOL DIAGN 2015;17 (1):43-52 [PubMed]
von Stedingk K, de Preter K, Vandesompele J, Noguera R, Øra I, Koster J, Versteeg R, Påhlman S, Lindgren D, Axelson H, Individual patient risk stratification of high-risk neuroblastomas using a two-gene score suited for clinical use. INT J CANCER 2015;137 (4):868-877 [PubMed]
Wegert J, Ishaque N, Vardapour R, Geörg C, Gu Z, Bieg M, Ziegler B, Bausenwein S, Nourkami N, Ludwig N, Keller A, Grimm C, Kneitz S, Williams RD, Chagtai T, Pritchard-Jones K, van Sluis P, Volckmann R, Koster J, Versteeg R, Acha T, O'Sullivan MJ, Bode PK, Niggli F, Tytgat GA, van Tinteren H, van den Heuvel-Eibrink MM, Meese E, Vokuhl C, Leuschner I, Graf N, Eils R, Pfister SM, Kool M, Gessler M, Mutations in the SIX1/2 Pathway and the DROSHA/DGCR8 miRNA Microprocessor Complex Underlie High-Risk Blastemal Type Wilms Tumors. CANCER CELL 2015;27 (2):298-311 [PubMed]
Yang J, AlTahan AM, Hu D, Wang Y, Cheng PH, Morton CL, Qu C, Nathwani AC, Shohet JM, Fotsis T, Koster J, Versteeg R, Okada H, Harris AL, Davidoff AM, The Role of Histone Demethylase KDM4B in Myc Signaling in Neuroblastoma. JNCI-J NATL CANCER I 2015;107 (6):djv080 [PubMed]
Barbieri E, de Preter K, Capasso M, Chen Z, Hsu DM, Tonini GP, Lefever S, Hicks J, Versteeg R, Pession A, Speleman F, Kim ES, Shohet JM, Histone chaperone CHAF1A inhibits differentiation and promotes aggressive neuroblastoma. CANCER RES 2014;74 (3):765-774 [PubMed]
Bate-Eya LT, Ebus ME, Koster J, den Hartog IJM, Zwijnenburg DA, Schild L, van der Ploeg I, Dolman MEM, Caron HN, Versteeg R, Molenaar JJ, Newly-derived neuroblastoma cell lines propagated in serum-free media recapitulate the genotype and phenotype of primary neuroblastoma tumours. EUR J CANCER 2014;50 (3):628-637 [PubMed]
Bryan K, Terrile M, Bray IM, Domingo-Fernandéz R, Watters KM, Koster J, Versteeg R, Stallings RL, Discovery and visualization of miRNA-mRNA functional modules within integrated data using bicluster analysis. NUCLEIC ACIDS RES 2014;42 (3):e17 [PubMed]
Cangelosi D, Muselli M, Parodi S, Blengio F, Becherini P, Versteeg R, Conte M, Varesio L, Use of Attribute Driven Incremental Discretization and Logic Learning Machine to build a prognostic classifier for neuroblastoma patients. BMC BIOINFORMATICS 2014;15 (Suppl. 5):S4 [PubMed]
Hovestadt V, Jones DTW, Picelli S, Wang W, Kool M, Northcott PA, Sultan M, Stachurski K, Ryzhova M, Warnatz HJ, Ralser M, Brun S, Bunt J, Jäger N, Kleinheinz K, Erkek S, Weber UD, Bartholomae CC, von Kalle C, Lawerenz C, Eils J, Koster J, Versteeg R, Milde T, Witt O, Schmidt S, Wolf S, Pietsch T, Rutkowski S, Scheurlen W, Taylor MD, Brors B, Felsberg J, Reifenberger G, Borkhardt A, Lehrach H, Wechsler-Reya RJ, Eils R, Yaspo ML, Landgraf P, Korshunov A, Zapatka M, Radlwimmer B, Pfister SM, Lichter P, Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing. NATURE 2014;510 (7506):537-541 [PubMed]
Kool M, Jones DTW, Jäger N, Northcott PA, Pugh TJ, Hovestadt V, Piro RM, Esparza LA, Markant SL, Remke M, Milde T, Bourdeaut F, Ryzhova M, Sturm D, Pfaff E, Stark S, Hutter S, Seker-Cin H, Johann P, Bender S, Schmidt C, Rausch T, Shih D, Reimand J, Sieber L, Wittmann A, Linke L, Witt H, Weber UD, Zapatka M, König R, Beroukhim R, Bergthold G, van Sluis P, Volckmann R, Koster J, Versteeg R, Schmidt S, Wolf S, Lawerenz C, Bartholomae CC, von Kalle C, Unterberg A, Herold-Mende C, Hofer S, Kulozik AE, von Deimling A, Scheurlen W, Felsberg J, Reifenberger G, Hasselblatt M, Crawford JR, Grant GA, Jabado N, Perry A, Cowdrey C, Croul S, Zadeh G, Korbel JO, Doz F, Delattre O, Bader GD, McCabe MG, Collins VP, Kieran MW, Cho YJ, Pomeroy SL, Witt O, Brors B, Taylor MD, Schüller U, Korshunov A, Eils R, Wechsler-Reya RJ, Lichter P, Pfister SM, Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. CANCER CELL 2014;25 (3):393-405 [PubMed]
Lee S, Rahnenführer J, Lang M, de Preter K, Mestdagh P, Koster J, Versteeg R, Stallings RL, Varesio L, Asgharzadeh S, Schulte JH, Fielitz K, Schwermer M, Morik K, Schramm A, Robust selection of cancer survival signatures from high-throughput genomic data using two-fold subsampling. PLOS ONE 2014;9 (10):e108818 [PubMed]
Northcott PA, Lee C, Zichner T, Stütz AM, Erkek S, Kawauchi D, Shih DJH, Hovestadt V, Zapatka M, Sturm D, Jones DTW, Kool M, Remke M, Cavalli FMG, Zuyderduyn S, Bader GD, VandenBerg S, Esparza LA, Ryzhova M, Wang W, Wittmann A, Stark S, Sieber L, Seker-Cin H, Linke L, Kratochwil F, Jäger N, Buchhalter I, Imbusch CD, Zipprich G, Raeder B, Schmidt S, Diessl N, Wolf S, Wiemann S, Brors B, Lawerenz C, Eils J, Warnatz HJ, Risch T, Yaspo ML, Weber UD, Bartholomae CC, von Kalle C, Turányi E, Hauser P, Sanden E, Darabi A, Siesjö P, Sterba J, Zitterbart K, Sumerauer D, van Sluis P, Versteeg R, Volckmann R, Koster J, Schuhmann MU, Ebinger M, Grimes HL, Robinson GW, Gajjar A, Mynarek M, von Hoff K, Rutkowski S, Pietsch T, Scheurlen W, Felsberg J, Reifenberger G, Kulozik AE, von Deimling A, Witt O, Eils R, Gilbertson RJ, Korshunov A, Taylor MD, Lichter P, Korbel JO, Wechsler-Reya RJ, Pfister SM, Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma. NATURE 2014;511 (7510):428-434 [PubMed]
Rihani A, de Wilde B, Zeka F, Laureys G, Francotte N, Tonini GP, Coco S, Versteeg R, Noguera R, Schulte JH, Eggert A, Stallings RL, Speleman F, Vandesompele J, van Maerken T, CASP8 SNP D302H (rs1045485) is associated with worse survival in MYCN-amplified neuroblastoma patients. PLOS ONE 2014;9 (12):e114696 [PubMed]
Rihani A, van Maerken T, de Wilde B, Zeka F, Laureys G, Norga K, Tonini GP, Coco S, Versteeg R, Noguera R, Schulte JH, Eggert A, Stallings RL, Speleman F, Vandesompele J, Lack of association between MDM2 promoter SNP309 and clinical outcome in patients with neuroblastoma. PEDIATR BLOOD CANCER 2014;61 (10):1867-1870 [PubMed]
Sero V, Tavanti E, Vella S, Hattinger CM, Fanelli M, Michelacci F, Versteeg R, Valsasina B, Gudeman B, Picci P, Serra M, Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance. INVEST NEW DRUG 2014;32 (6):1167-1180 [PubMed]
Verhaegh W, van Ooijen H, Inda MA, Hatzis P, Versteeg R, Smid M, Martens J, Foekens J, van de Wiel P, Clevers H, van de Stolpe A, Selection of personalized patient therapy through the use of knowledge-based computational models that identify tumor-driving signal transduction pathways. CANCER RES 2014;74 (11):2936-2945 [PubMed]
Versteeg R, CANCER Tumours outside the mutation box. NATURE 2014;506 (7489):438-439 [PubMed]
Bunt J, Hasselt NA, Zwijnenburg DA, Koster J, Versteeg R, Kool M, OTX2 sustains a bivalent-like state of OTX2-bound promoters in medulloblastoma by maintaining their H3K27me3 levels. ACTA NEUROPATHOL 2013;125 (3):385-394 [PubMed]
Cangelosi D, Blengio F, Versteeg R, Eggert A, Garaventa A, Gambini C, Conte M, Eva A, Muselli M, Varesio L, Logic Learning Machine creates explicit and stable rules stratifying neuroblastoma patients. BMC BIOINFORMATICS 2013;14 (Suppl. 7):S12 [PubMed]
Das S, Bryan K, Buckley PG, Piskareva O, Bray IM, Foley N, Ryan J, Lynch J, Creevey L, Fay J, Prenter S, Koster J, van Sluis P, Versteeg R, Eggert A, Schulte JH, Schramm A, Mestdagh P, Vandesompele J, Speleman F, Stallings RL, Modulation of neuroblastoma disease pathogenesis by an extensive network of epigenetically regulated microRNAs. ONCOGENE 2013;32 (24):2927-2936 [PubMed]
Jäger N, Schlesner M, Jones DTW, Raffel S, Mallm JP, Junge KM, Weichenhan D, Bauer T, Ishaque N, Kool M, Northcott PA, Korshunov A, Drews RM, Koster J, Versteeg R, Richter J, Hummel M, Mack SC, Taylor MD, Witt H, Swartman B, Schulte-Bockholt D, Sultan M, Yaspo ML, Lehrach H, Hutter B, Brors B, Wolf S, Plass C, Siebert R, Trumpp A, Rippe K, Lehmann I, Lichter P, Pfister SM, Eils R, Hypermutation of the inactive X chromosome is a frequent event in cancer. CELL 2013;155 (3):567-581 [PubMed]
Jones DTW, Hutter B, Jäger N, Korshunov A, Kool M, Warnatz HJ, Zichner T, Lambert SR, Ryzhova M, Quang DAK, Fontebasso AM, Stütz AM, Hutter S, Zuckermann M, Sturm D, Gronych J, Lasitschka B, Schmidt S, Seker-Cin H, Witt H, Sultan M, Ralser M, Northcott PA, Hovestadt V, Bender S, Pfaff E, Stark S, Faury D, Schwartzentruber J, Majewski J, Weber UD, Zapatka M, Raeder B, Schlesner M, Worth CL, Bartholomae CC, von Kalle C, Imbusch CD, Radomski S, Lawerenz C, van Sluis P, Koster J, Volckmann R, Versteeg R, Lehrach H, Monoranu C, Winkler B, Unterberg A, Herold-Mende C, Milde T, Kulozik AE, Ebinger M, Schuhmann MU, Cho YJ, Pomeroy SL, von Deimling A, Witt O, Taylor MD, Wolf S, Karajannis MA, Eberhart CG, Scheurlen W, Hasselblatt M, Ligon KL, Kieran MW, Korbel JO, Yaspo ML, Brors B, Felsberg J, Reifenberger G, Collins VP, Jabado N, Eils R, Lichter P, Pfister SM [Contributors: Pfister SM]] , Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. NAT GENET 2013;45 (8):927-932 [PubMed]
Kocemba KA, van Andel H, de Haan-Kramer A, Mahtouk K, Versteeg R, Kersten MJ , Spaargaren M, Pals ST, The hypoxia target adrenomedullin is aberrantly expressed in multiple myeloma and promotes angiogenesis. LEUKEMIA 2013;27 (8):1729-1737 [PubMed]
Lundberg G, Jin Y, Sehic D, Øra I, Versteeg R, Gisselsson D, Intratumour diversity of chromosome copy numbers in neuroblastoma mediated by on-going chromosome loss from a polyploid state. PLOS ONE 2013;8 (3):e59268 [PubMed]
Santo EE, Stroeken P, Sluis PV, Koster J, Versteeg R, Westerhout EM, FOXO3a is a major target of inactivation by PI3K/AKT signaling in aggressive neuroblastoma. CANCER RES 2013;73 (7):2189-2198 [PubMed]
Schulte JH, Lindner S, Bohrer A, Maurer J, de Preter K, Lefever S, Heukamp L, Schulte S, Molenaar J, Versteeg R, Thor T, Künkele A, Vandesompele J, Speleman F, Schorle H, Eggert A, Schramm A, MYCN and ALKF1174L are sufficient to drive neuroblastoma development from neural crest progenitor cells. ONCOGENE 2013;32 (8):1059-1065 [PubMed]
Tavanti E, Sero V, Vella S, Fanelli M, Michelacci F, Landuzzi L, Magagnoli G, Versteeg R, Picci P, Hattinger CM, Serra M, Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma. BRIT J CANCER 2013;109 (10):2607-2618 [PubMed]
van Nes J, Chan A, van Groningen T , van Sluis P, Koster J, Versteeg R, A NOTCH3 transcriptional module induces cell motility in neuroblastoma. CLIN CANCER RES 2013;19 (13):3485-3494 [PubMed]
von Stedingk K, Koster J, Piqueras M, Noguera R, Navarro S, Påhlman S, Versteeg R, Ora I, Gisselsson D, Lindgren D, Axelson H, snoRNPs Regulate Telomerase Activity in Neuroblastoma and Are Associated with Poor Prognosis. TRANSL ONCOL 2013;6 (4):447-U142 [PubMed]
Wilzén A, Krona C, Sveinbjörnsson B, Kristiansson E, Dalevi D, Øra I, de Preter K, Stallings RL, Maris J, Versteeg R, Nilsson S, Kogner P, Abel F, ERBB3 is a marker of a ganglioneuroblastoma/ganglioneuroma-like expression profile in neuroblastic tumours. MOL CANCER 2013;12 (1):70 [PubMed]
Zeilstra J, Joosten SPJ, Vermeulen L, Koster J, Medema JP, Versteeg R, Spaargaren M, Pals ST, CD44 expression in intestinal epithelium and colorectal cancer is independent of p53 status. PLOS ONE 2013;8 (8):e72849 [PubMed]
Bunt J. The role of OTX2 in medulloblastoma. s.l.: s.n.; 2012. 167p. ISBN 9789462031586 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Versteeg R; copromotor(s): Kool M)
Bunt J, Hasselt NE, Zwijnenburg DA, Hamdi M, Koster J, Versteeg R, Kool M, OTX2 directly activates cell cycle genes and inhibits differentiation in medulloblastoma cells. INT J CANCER 2012;131 (2):E21-E32 [PubMed]
Cornero A, Acquaviva M, Fardin P, Versteeg R, Schramm A, Eva A, Bosco MC, Blengio F, Barzaghi S, Varesio L, Design of a multi-signature ensemble classifier predicting neuroblastoma patients' outcome. BMC BIOINFORMATICS 2012;13 (4):S13 [PubMed]
Fieuw A, Kumps C, Schramm A, Pattyn F, Menten B, Antonacci F, Sudmant P, Schulte JH, van Roy N, Vergult S, Buckley PG, de Paepe A, Noguera R, Versteeg R, Stallings R, Eggert A, Vandesompele J, de Preter K, Speleman F, Identification of a novel recurrent 1q42.2-1qter deletion in high risk MYCN single copy 11q deleted neuroblastomas. INT J CANCER 2012;130 (11):2599-2606 [PubMed]
Kemper K, Versloot M, Cameron K, Colak S, de Sousa E Melo F, de Jong JH, Bleackley J, Vermeulen L, Versteeg R, Koster J, Medema JP, Mutations in the Ras-Raf Axis Underlie the Prognostic Value of CD133 in Colorectal Cancer. CLIN CANCER RES 2012;18 (11):3132-3141 [PubMed]
Korshunov A, Ryzhova M, Jones DTW, Northcott PA, van Sluis P, Volckmann R, Koster J, Versteeg R, Cowdrey C, Perry A, Picard D, Rosenblum M, Giangaspero F, Aronica E, Schüller U, Hasselblatt M, Collins VP, von Deimling A, Lichter P, Huang A, Pfister SM, Kool M, LIN28A immunoreactivity is a potent diagnostic marker of embryonal tumor with multilayered rosettes (ETMR). ACTA NEUROPATHOL 2012;124 (6):875-881 [PubMed]
Lamers F, Schild L, den Hartog IJM, Ebus ME, Westerhout EM, Ora I, Koster J, Versteeg R, Caron HN, Molenaar JJ, Targeted BCL2 inhibition effectively inhibits neuroblastoma tumour growth. EUR J CANCER 2012;48 (16):3093-3103 [PubMed]
Lamers F, Schild L, Koster J, Speleman F, Øra I, Westerhout EM, van Sluis P, Versteeg R, Caron HN, Molenaar JJ, Identification of BIRC6 as a novel intervention target for neuroblastoma therapy. BMC CANCER 2012;12 (1):285 [PubMed]
Lamers F, Schild L, Koster J, Versteeg R, Caron HN, Molenaar JJ, Targeted BIRC5 silencing using YM155 causes cell death in neuroblastoma cells with low ABCB1 expression. EUR J CANCER 2012;48 (5):763-771 [PubMed]
Lamers SGM. New therapeutic targets in the intrinsic apoptotic pathway in neuroblastoma. s.l.: s.n.; 2012. 135p. ISBN 9789462030404 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Versteeg R, Caron HN; copromotor(s): Molenaar JJ)
Molenaar JJ, Domingo-Fernández R, Ebus ME, Lindner S, Koster J, Drabek K, Mestdagh P, van Sluis P, Valentijn LJ, van Nes J, Broekmans M, Haneveld F, Volckmann R, Bray I, Heukamp L, Sprüssel A, Thor T, Kieckbusch K, Klein-Hitpass L, Fischer M, Vandesompele J, Schramm A, van Noesel MM, Varesio L, Speleman F, Eggert A, Stallings RL, Caron HN, Versteeg R, Schulte JH, LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. NAT GENET 2012;44 (11):1199-1206 [PubMed]
Molenaar JJ, Koster J, Ebus ME, van Sluis P, Westerhout EM, de Preter K, Gisselsson D, Øra I, Speleman F, Caron HN, Versteeg R, Copy Number Defects of G1-Cell Cycle Genes in Neuroblastoma are Frequent and Correlate with High Expression of E2F Target Genes and a Poor Prognosis. GENE CHROMOSOME CANC 2012;51 (1):10-19 [PubMed]
Molenaar JJ, Koster J, Zwijnenburg DA, van Sluis P, Valentijn LJ, van der Ploeg I, Hamdi M, van Nes J, Westerman BA, van Arkel J, Ebus ME, Haneveld F, Lakeman A, Schild L, Molenaar P, Stroeken P, van Noesel MM, Ora I, Santo EE, Caron HN, Westerhout EM, Versteeg R, Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. NATURE 2012;483 (7391):589-U107 [PubMed]
Muñoz J, Stange DE, Schepers AG, van de Wetering M, Koo BK, Itzkovitz S, Volckmann R, Kung KS, Koster J, Radulescu S, Myant K, Versteeg R, Sansom OJ, van Es JH, Barker N, van Oudenaarden A, Mohammed S, Heck AJR, Clevers H, The Lgr5 intestinal stem cell signature: robust expression of proposed quiescent '+4' cell markers. EMBO J 2012;31 (14):3079-3091 [PubMed]
Orlova DY, Stixová L, Kozubek S, Gierman HJ, Šustáčková G, Chernyshev AV, Medvedev RN, Legartová S, Versteeg R, Matula P, Stoklasa R, Bártová E, Arrangement of nuclear structures is not transmitted through mitosis but is identical in sister cells. J CELL BIOCHEM 2012;113 (11):3313-3329 [PubMed]
Rausch T, Jones DTW, Zapatka M, Stütz AM, Zichner T, Weischenfeldt J, Jäger N, Remke M, Shih D, Northcott PA, Pfaff E, Tica J, Wang Q, Massimi L, Witt H, Bender S, Pleier S, Cin H, Hawkins C, Beck C, von Deimling A, Hans V, Brors B, Eils R, Scheurlen W, Blake J, Benes V, Kulozik AE, Witt O, Martin D, Zhang C, Porat R, Merino DM, Wasserman J, Jabado N, Fontebasso A, Bullinger L, Rücker FG, Döhner K, Döhner H, Koster J, Molenaar JJ, Versteeg R, Kool M, Tabori U, Malkin D, Korshunov A, Taylor MD, Lichter P, Pfister SM, Korbel JO, Genome Sequencing of Pediatric Medulloblastoma Links Catastrophic DNA Rearrangements with TP53 Mutations. CELL 2012;148 (1-2):59-71 [PubMed]
Santo EE , Ebus ME, Koster J, Schulte JH, Lakeman A, van Sluis P, Vermeulen J, Gisselsson D, Øra I, Lindner S, Buckley PG, Stallings RL, Vandesompele J, Eggert A, Caron HN, Versteeg R, Molenaar JJ, Oncogenic activation of FOXR1 by 11q23 intrachromosomal deletion-fusions in neuroblastoma. ONCOGENE 2012;31 (12):1571-1581 [PubMed]
Schramm A, Schowe B, Fielitz K, Heilmann M, Martin M, Marschall T, Köster J, Vandesompele J, Vermeulen J, de Preter K, Koster J, Versteeg R, Noguera R, Speleman F, Rahmann S, Eggert A, Morik K, Schulte JH, Exon-level expression analyses identify MYCN and NTRK1 as major determinants of alternative exon usage and robustly predict primary neuroblastoma outcome. BRIT J CANCER 2012;107 (8):1409-1417 [PubMed]
Sturm D, Witt H, Hovestadt V, Khuong-Quang DA, Jones DTW, Konermann C, Pfaff E, Tönjes M, Sill M, Bender S, Kool M, Zapatka M, Becker N, Zucknick M, Hielscher T, Liu XY, Fontebasso AM, Ryzhova M, Albrecht S, Jacob K, Wolter M, Ebinger M, Schuhmann MU, van Meter T, Frühwald MC, Hauch H, Pekrun A, Radlwimmer B, Niehues T, von Komorowski G, Dürken M, Kulozik AE, Madden J, Donson A, Foreman NK, Drissi R, Fouladi M, Scheurlen W, von Deimling A, Monoranu C, Roggendorf W, Herold-Mende C, Unterberg A, Kramm CM, Felsberg J, Hartmann C, Wiestler B, Wick W, Milde T, Witt O, Lindroth AM, Schwartzentruber J, Faury D, Fleming A, Zakrzewska M, Liberski PP, Zakrzewski K, Hauser P, Garami M, Klekner A, Bognar L, Morrissy S, Cavalli F, Taylor MD, van Sluis P, Koster J, Versteeg R, Volckmann R, Mikkelsen T, Aldape K, Reifenberger G, Collins VP, Majewski J, Korshunov A, Lichter P, Plass C, Jabado N, Pfister SM, Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma. CANCER CELL 2012;22 (4):425-437 [PubMed]
Stutterheim J, Ichou FA, den Ouden E, Versteeg R, Caron HN, Tytgat GAM, van der Schoot CE, Methylated RASSF1a Is the First Specific DNA Marker for Minimal Residual Disease Testing in Neuroblastoma. CLIN CANCER RES 2012;18 (3):808-814 [PubMed]
Stutterheim J, Zappeij-Kannegieter L, Ora I, van Sluis PG, Bras J, den Ouden E, Versteeg R, Caron HN, van der Schoot CE, Tytgat GAM, Stability of PCR Targets for Monitoring Minimal Residual Disease in Neuroblastoma. J MOL DIAGN 2012;14 (2):168-175 [PubMed]
Valentijn LJ, Koster J, Haneveld F, Aissa RA, van Sluis P, Broekmans MEC, Molenaar JJ, van Nes J, Versteeg R, Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification. P NATL ACAD SCI USA 2012;109 (47):19190-19195 [PubMed]
Buckley PG, Das S, Bryan K, Watters KM, Alcock L, Koster J, Versteeg R, Stallings RL, Genome-wide DNA methylation analysis of neuroblastic tumors reveals clinically relevant epigenetic events and large-scale epigenomic alterations localized to telomeric regions. INT J CANCER 2011;128 (10):2296-2305 [PubMed]
Bunt J, Hasselt NE, Zwijnenburg DA, Koster J, Versteeg R, Kool M, Joint binding of OTX2 and MYC in promotor regions is associated with high gene expression in medulloblastoma. PLOS ONE 2011;6 (10):e26058 [PubMed]
de Preter K, Mestdagh P, Vermeulen J, Zeka F, Naranjo A, Bray I, Castel V, Chen C, Drozynska E, Eggert A, Hogarty MD, Izycka-Swieszewska E, London WB, Noguera R, Piqueras M, Bryan K, Schowe B, van Sluis P, Molenaar JJ, Schramm A, Schulte JH, Stallings RL, Versteeg R, Laureys G, van Roy N, Speleman F, Vandesompele J, miRNA expression profiling enables risk stratification in archived and fresh neuroblastoma tumor samples. CLIN CANCER RES 2011;17 (24):7684-7692 [PubMed]
de Sousa E Melo F, Colak S, Buikhuisen J, Koster J, Cameron K, de Jong JH, Tuynman JB, Prasetyanti PR, Fessler E, van den Bergh SP, Rodermond H, Dekker E, van der Loos CM, Pals ST, van de Vijver MJ, Versteeg R, Richel DJ, Vermeulen L, Medema JP, Methylation of cancer-stem-cell-associated Wnt target genes predicts poor prognosis in colorectal cancer patients. CELL STEM CELL 2011;9 (5):476-485 [PubMed]
Lamers F, van der Ploeg I, Schild L, Ebus ME, Koster J, Hansen BR, Koch T, Versteeg R, Caron HN, Molenaar JJ, Knockdown of survivin (BIRC5) causes apoptosis in neuroblastoma via mitotic catastrophe. ENDOCR-RELAT CANCER 2011;18 (6):657-668 [PubMed]
Murphy DM, Buckley PG, Bryan K, Watters KM, Koster J, van Sluis P, Molenaar J, Versteeg R, Stallings RL, Dissection of the Oncogenic MYCN Transcriptional Network Reveals a Large Set of Clinically Relevant Cell Cycle Genes as Drivers of Neuroblastoma Tumorigenesis. MOL CARCINOGEN 2011;50 (6):403-411 [PubMed]
Stutterheim J, Zappeij-Kannegieter L, Versteeg R, Caron HN, van der Schoot CE, Tytgat GAM, The prognostic value of fast molecular response of marrow disease in patients aged over 1 year with stage 4 neuroblastoma. EUR J CANCER 2011;47 (8):1193-1202 [PubMed]
Teller K, Illner D, Thamm S, Casas-Delucchi CS, Versteeg R, Indemans M, Cremer T, Cremer M, A top-down analysis of Xa- and Xi-territories reveals differences of higher order structure at ≥ 20 Mb genomic length scales. NUCLEUS-PHILA 2011;2 (5):465-477 [PubMed]
Bunt J, de Haas TG, Hasselt NE, Zwijnenburg DA, Koster J, Versteeg R, Kool M, Regulation of cell cycle genes and induction of senescence by overexpression of OTX2 in medulloblastoma cell lines. MOL CANCER RES 2010;8 (10):1344-1357 [PubMed]
de Brouwer S, de Preter K, Kumps C, Zabrocki P, Porcu M, Westerhout EM, Lakeman A, Vandesompele J, Hoebeeck J, van Maerken T, de Paepe A, Laureys G, Schulte JH, Schramm A, van den Broecke C, Vermeulen J, van Roy N, Beiske K, Renard M, Noguera R, Delattre O, Janoueix-Lerosey I, Kogner P, Martinsson T, Nakagawara A, Ohira M, Caron HN, Eggert A, Cools J, Versteeg R, Speleman F, Meta-analysis of Neuroblastomas Reveals a Skewed ALK Mutation Spectrum in Tumors with MYCN Amplification. CLIN CANCER RES 2010;16 (17):4353-4362 [PubMed]
Fardin P, Barla A, Mosci S, Rosasco L, Verri A, Versteeg R, Caron HN, Molenaar JJ, Ora I, Eva A, Puppo M, Varesio L, A biology-driven approach identifies the hypoxia gene signature as a predictor of the outcome of neuroblastoma patients. MOL CANCER 2010;9 (1):185 [PubMed]
Geerts D, Koster J, Albert D, Koomoa DLT, Feith DJ, Pegg AE, Volckmann R, Caron H, Versteeg R, Bachmann AS, The polyamine metabolism genes ornithine decarboxylase and antizyme 2 predict aggressive behavior in neuroblastomas with and without MYCN amplification. INT J CANCER 2010;126 (9):2012-2024 [PubMed]
Gierman HJ. Gene expression in chromosomal ridge domains. Influence on transcription, mRNA stability, codon usage, and evolution. S.l.: s.n.; 2010. 168p. ISBN 9789090253053 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Versteeg R; copromotor(s): )
Hölzel M, Huang S, Koster J, Ora I, Lakeman A, Caron H, Nijkamp W, Xie J, Callens T, Asgharzadeh S, Seeger RC, Messiaen L, Versteeg R, Bernards R, NF1 Is a Tumor Suppressor in Neuroblastoma that Determines Retinoic Acid Response and Disease Outcome. CELL 2010;142 (2):218-229 [PubMed]
Mokry M, Hatzis P, de Bruijn E, Koster J, Versteeg R, Schuijers J, van de Wetering M, Guryev V, Clevers H, Cuppen E, Efficient Double Fragmentation ChIP-seq Provides Nucleotide Resolution Protein-DNA Binding Profiles. PLOS ONE 2010;5 (11):e15092 [PubMed]
Molenaar JJ , Ebus ME, Koster J, Santo E, Geerts D, Versteeg R, Caron HN, Cyclin D1 is a direct transcriptional target of GATA3 in neuroblastoma tumor cells. ONCOGENE 2010;29 (18):2739-2745 [PubMed]
Revet I, Huizenga G, Koster J, Volckmann R, van Sluis P, Versteeg R, Geerts D, MSX1 induces the Wnt pathway antagonist genes DKK1, DKK2, DKK3, and SFRP1 in neuroblastoma cells, but does not block Wnt3 and Wnt5A signalling to DVL3. CANCER LETT 2010;289 (2):195-207 [PubMed]
Revet IM. Homeobox genes in neuroblastoma. s.l.: s.n.; 2010. 175p. ISBN 9789090253114 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Versteeg R; copromotor(s): Geerts D)
Schaaf G, Hamdi M, Zwijnenburg D, Lakeman A, Geerts D, Versteeg R, Kool M, Silencing of SPRY1 Triggers Complete Regression of Rhabdomyosarcoma Tumors Carrying a Mutated RAS Gene. CANCER RES 2010;70 (2):762-771 [PubMed]
Verissimo CS, Molenaar JJ, Meerman J, Puigvert JC, Lamers F, Koster J, Danen E, van de Water B, Versteeg R, Fitzsimons CP, Vreugdenhil E, Silencing of the microtubule-associated proteins doublecortin-like and doublecortin-like kinase-long induces apoptosis in neuroblastoma cells. ENDOCR-RELAT CANCER 2010;17 (2):399-414 [PubMed]
Cimmino F, Schulte JH, Zollo M, Koster J, Versteeg R, Iolascon A, Eggert A, Schramm A, Galectin-1 is a major effector of TrkB-mediated neuroblastoma aggressiveness. ONCOGENE 2009;28 (19):2015-2023 [PubMed]
Huang S, Laoukili J, Epping MT, Koster J, Hölzel M, Westerman BA, Nijkamp W, Hata A, Asgharzadeh S, Seeger RC, Versteeg R, Beijersbergen RL, Bernards R, ZNF423 is critically required for retinoic acid-induced differentiation and is a marker of neuroblastoma outcome. CANCER CELL 2009;15 (4):328-340 [PubMed]
Missiaglia E, Selfe J, Hamdi M, Williamson D, Schaaf G, Fang C, Koster J, Summersgill B, Messahel B, Versteeg R, Pritchard-Jones K, Kool M, Shipley J, Genomic Imbalances in Rhabdomyosarcoma Cell Lines Affect Expression of Genes Frequently Altered in Primary Tumors: An Approach to Identify Candidate Genes Involved in Tumor Development. GENE CHROMOSOME CANC 2009;48 (6):455-467 [PubMed]
Molenaar JJ. The cell cycle in neuroblastoma. From genomic aberrations to targeted intervention. s.l.: s.n.; 2009. 132p. ISBN 9789090245003 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Caron HN, Versteeg R; copromotor(s): )
Molenaar JJ, Ebus ME, Geerts D, Koster J, Lamers F, Valentijn LJ, Westerhout EM, Versteeg R, Caron HN, Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells. P NATL ACAD SCI USA 2009;106 (31):12968-12973 [PubMed]
Schulte JH, Lim S, Schramm A, Friedrichs N, Koster J, Versteeg R, Ora I, Pajtler K, Klein-Hitpass L, Kuhfittig-Kulle S, Metzger E, Schüle R, Eggert A, Buettner R, Kirfel J, Lysine-Specific Demethylase 1 Is Strongly Expressed in Poorly Differentiated Neuroblastoma: Implications for Therapy. CANCER RES 2009;69 (5):2065-2071 [PubMed]
Schulte JH, Pentek F, Hartmann W, Schramm A, Friedrichs N, Ora I, Koster J, Versteeg R, Kirfel J, Buettner R, Eggert A, The low-affinity neurotrophin receptor, p75, is upregulated in ganglioneuroblastoma/ganglioneuroma and reduces tumorigenicity of neuroblastoma cells in vivo. INT J CANCER 2009;124 (10):2488-2494 [PubMed]
Stutterheim J, Gerritsen A, Zappeij-Kannegieter L, Yalcin B, dee R, van Noesel MM, Berthold F, Versteeg R, Caron HN, van der Schoot CE, Tytgat GAM, Detecting Minimal Residual Disease in Neuroblastoma: The Superiority of a Panel of Real-Time Quantitative PCR Markers. CLIN CHEM 2009;55 (7):1316-1326 [PubMed]
van Engelen K, Merks JHM, Lam J, Kremer LCM, Backes M, Baars MJH, van der Pal HJH, Postma AV, Versteeg R, Caron HN, Mulder BJM, Prevalence of congenital heart defects in neuroblastoma patients: a cohort study and systematic review of literature. EUR J PEDIATR 2009;168 (9):1081-1090 [PubMed]
van Hooff SR, Koster J, Hulsen T, van Schaik BDC, Roos M, van Batenburg MF, Versteeg R, van Kampen AHC, The Construction of Genome-Based Transcriptional Units. OMICS 2009;13 (2):105-114 [PubMed]
de Haas T, Hasselt N, Troost D, Caron H, Popovic M, Zadravec-Zaletel L, Grajkowska W, Perek M, Osterheld MC, Ellison D, Baas F, Versteeg R, Kool M, Molecular risk stratification of medulloblastoma patients based on immunohistochemical analysis of MYC, LDHB, and CCNB1 expression. CLIN CANCER RES 2008;14 (13):4154-4160 [PubMed]
Gierman HJ, Versteeg R. Clustering of highly expressed genes in the human genome. in: N. N, editor. Encyclopedia of life sciences (eLS). Chichester: John Wiley & Sons Ltd; 2005. april, p. 1-4
Hatzis P, van der Flier LG, van Driel MA, Guryev V, Nielsen F, Denissov S, Nijman IJ, Koster J, Santo EE, Welboren W, Versteeg R, Cuppen E, van de Wetering M, Clevers H, Stunnenberg HG, Genome-wide pattern of TCF7L2/TCF4 chromatin occupancy in colorectal cancer cells. MOL CELL BIOL 2008;28 (8):2732-2744 [PubMed]
Kool M, Koster J, Bunt J, Hasselt NE, Lakeman A, van Sluis P, Troost D, Schouten-van Meeteren NAY, Caron HN, Cloos J, Mrsić A, Ylstra B, Grajkowska W, Hartmann W, Pietsch T, Ellison D, Clifford SC, Versteeg R, Integrated Genomics Identifies Five Medulloblastoma Subtypes with Distinct Genetic Profiles, Pathway Signatures and Clinicopathological Features. PLOS ONE 2008;3 (8):e3088 [PubMed]
Koppen A. Gene regulation by MYCN in neuroblastoma. s.l.: s.n.; 2008. 152p. [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Versteeg R; copromotor(s): Valentijn LJ)
Koppen A, Ait-Aissa R, Koster J, Øra I, Bras J, van Sluis PG, Caron H, Versteeg R, Valentijn LJ, Dickkopf-3 expression is a marker for neuroblastic tumor maturation and is down-regulated by MYCN. INT J CANCER 2008;122 (7):1455-1464 [PubMed]
Molenaar JJ, Ebus ME, Koster J, van Sluis P, van Noesel CJM, Versteeg R, Caron HN, Cyclin D1 and CDK4 activity contribute to the undifferentiated phenotype in neuroblastoma. CANCER RES 2008;68 (8):2599-2609 [PubMed]
Revet I, Huizenga G, Chan A, Koster J, Volckmann R, van Sluis P, Øra I, Versteeg R, Geerts D, The MSX1 homeobox transcription factor is a downstream target of PHOX2B and activates the Delta-Notch pathway in neuroblastoma. EXP CELL RES 2008;314 (4):707-719 [PubMed]
Stutterheim J, Gerritsen A, Zappeij-Kannegieter L, Kleijn I, dee R, Hooft L, van Noesel MM, Bierings M, Berthold F, Versteeg R, Caron HN, van der Schoot CE, Tytgat GAM, PHOX2B Is a Novel and Specific Marker for Minimal Residual Disease Testing in Neuroblastoma. J CLIN ONCOL 2008;26 (33):5443-5449 [PubMed]
Geerts D, Wallick CJ, Koomoa DLT, Koster J, Versteeg R, Go RCV, Bachmann AS, Expression of prenylated Rab acceptor 1 domain family, member 2 (PRAF2) in neuroblastoma: correlation with clinical features, cellular localization, and cerulenin-mediated apoptosis regulation. CLIN CANCER RES 2007;13 (21):6312-6319 [PubMed]
Gierman HJ, Indemans MHG, Koster J, Goetze S, Seppen J, Geerts D, van Driel R, Versteeg R, Domain-wide regulation of gene expression in the human genome. GENOME RES 2007;17 (9):1286-1295 [PubMed]
Goetze S, Mateos-Langerak J, Gierman HJ, de Leeuw W, Giromus O, Indemans MHG, Koster J, Ondrej V, Versteeg R, van Driel R, The three-dimensional structure of human interphase chromosomes is related to the transcriptome map. MOL CELL BIOL 2007;27 (12):4475-4487 [PubMed]
Henriksen JR, Lokke C, Hammero M, Geerts D, Versteeg R, Flaegstad T, Einvik C, Comparison of RNAi efficiency mediated by tetracycline-responsive H1 and U6 promoter variants in mammalian cell lines. NUCLEIC ACIDS RES 2007;35 (9):e67 [PubMed]
Koppen A, Ait-Aissa R, Hopman S, Koster J, Haneveld F, Versteeg R, Valentijn LJ, Dickkopf-1 is down-regulated by MYCN and inhibits neuroblastoma cell proliferation. CANCER LETT 2007;256 (2):218-228 [PubMed]
Koppen A, Ait-Aissa R, Koster J, van Sluis PG, Ora I, Caron HN, Volckmann R, Versteeg R, Valentijn LJ, Direct regulation of the minichromosome maintenance complex by MYCN in neuroblastoma. EUR J CANCER 2007;43 (16):2413-2422 [PubMed]
Michels E, Vandesompele J, de Preter K, Hoebeeck J, Vermeulen J, Schramm A, Molenaar JJ, Menten B, Marques B, Stallings RL, Combaret V, Devalck C, de Paepe A, Versteeg R, Eggert A, Laureys G, van Roy N, Speleman F, ArrayCGH-based classification of neuroblastoma into genomic subgroups. GENE CHROMOSOME CANC 2007;46 (12):1098-1108 [PubMed]
Zinner R, Teller K, Versteeg R, Cremer T, Cremer M, Biochemistry meets nuclear architecture: multicolor immuno-FISH for co-localization analysis of chromosome segments and differentially expressed gene loci with various histone methylations. ADV ENZYME REGUL 2007;47:223-241 [PubMed]
de Haas T, Oussoren E, Grajkowska W, Perek-Polnik M, Popovic M, Zadravec-Zaletel L, Perera M, Corte G, Wirths O, van Sluis P, Pietsch T, Troost D, Baas F, Versteeg R, Kool M, OTX1 and OTX2 expression correlates with the clinicopathologic classification of medulloblastomas. J NEUROPATH EXP NEUR 2006;65 (2):176-186 [PubMed]
Kester MHA, Kuiper GGJM, Versteeg R, Visser TJ, Regulation of type III iodothyronine deiodinase expression in human cell lines. ENDOCRINOLOGY 2006;147 (12):5845-5854 [PubMed]
Valentijn LJ, Koster J, Versteeg R, Read-through transcript from NM23-H1 into the neighboring NM23-H2 gene encodes a novel protein, NM23-LV. GENOMICS 2006;87 (4):483-489 [PubMed]
Geerts D, Revet I, Jorritsma G, Schilderink N, Versteeg R, MEIS homeobox genes in neuroblastoma. CANCER LETT 2005;228 (1-2):43-50 [PubMed]
Hienonen T, Sammalkorpi H, Isohanni P, Versteeg R, Karikoski R, Aaltonen LA, A 17p11.2 germline deletion in a patient with Smith-Magenis syndrome and neuroblastoma. J MED GENET 2005;42 (1):e3 [PubMed]
Mathay KK, Reynolds CP, Versteeg R. High-risk neuroblastoma: beyond intensification to novel therapy in: Perry Mc, editor. American society of clinical oncology educational book. S.l.: ASCO 2005; 2005., p. 786-797
Schramm A, Schulte JH, Astrahantseff K, Apostolov O, Limpt Vv, Sieverts H, Kuhfittig-Kulle S, Pfeiffer P, Versteeg R, Eggert A, Biological effects of TrkA and TrkB receptor signaling in neuroblastoma. CANCER LETT 2005;228 (1-2):143-153 [PubMed]
Valentijn LJ, Koppen A, van Asperen R, Root HA, Haneveld F, Versteeg R, Inhibition of a new differentiation pathway in neuroblastoma by copy number defects of N-myc, Cdc42, and nm23 genes. CANCER RES 2005;65 (8):3136-3145 [PubMed]
van Limpt VAME. Neuroblastoma, developmental control genes and cell fates decisions in the sympathetic nervous system. S.l.: s.n.; 2005. 155p. ISBN 90-9018878-9 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Versteeg R; copromotor(s): )
van Limpt V, Chan A, Schramm A, Eggert A, Versteeg R, Phox2B mutations and the Delta-Notch pathway in neuroblastoma. CANCER LETT 2005;228 (1-2):59-63 [PubMed]
van Noesel MM. Aberrant DNA hypermethylation and apoptotic defects in pediatric neuroblatomas. S.l.: s.n.; 2005. 115p. ISBN 90-9019026-0 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Versteeg R, Voute PA; copromotor(s): )
Versteeg R. Molecular biology of childhood tumours in: Voûte PA, Barrett A, Stevens M, Caron H, editors. Cancer in children-clinical management. 5th edition. Oxford: Oxford University Press; 2005.
van Limpt V, Schramm A, van Lakeman A, Sluis P, Chan A, van Noesel M, Baas F, Caron H, Eggert A, Versteeg R, The Phox2B homeobox gene is mutated in sporadic neuroblastomas. ONCOGENE 2004;23 (57):9280-9288 [PubMed]
van Noesel MM, Versteeg R, Pediatric neuroblastomas: genetic and epigenetic 'Danse Macabre'. GENE 2004;325:1-15 [PubMed]
Geerts D, Schilderink N, Jorritsma G, Versteeg R, The role of the MEIS homeobox genes in neuroblastoma. CANCER LETT 2003;197 (1-2):87-92 [PubMed]
Godfried MB. Role of nm23 in neuroblastoma. From genetic aberrations to pathways abnormalities. S.l.: s.n.; 2003. 114p. [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Caron HN; copromotor(s): Versteeg R)
Molenaar JJ, van Sluis P, Boon K, Versteeg R, Caron HN, Rearrangements and increased expression of cyclin D1 (CCND1) in neuroblastoma. GENE CHROMOSOME CANC 2003;36 (3):242-249 [PubMed]
van Kampen AHC, Ruijter JM, van Schaik BDC, Caron HN, Versteeg R. Gene expression informatics and analysis in: Barnes MR, Gray IC, editors. Bioinformatics for geneticists. Chichester: John Wiley & Sons; 2003., p. 319-344
van Limpt VAE, Chan AJ, van Sluis PG, Caron HN, van Noesel CJM, Versteeg R, High delta-like 1 expression in a subset of neuroblastoma cell lines corresponds to a differentiated chromaffin cell type. INT J CANCER 2003;105 (1):61-69 [PubMed]
van Noesel MM, Pieters R, Voûte PA, Versteeg R, The N-myc paradox: N-myc overexpression in neuroblastomas is associated with sensitivity as well as resistance to apoptosis. CANCER LETT 2003;197 (1-2):165-172 [PubMed]
van Noesel MM, van Bezouw S, Voûte PA, Herman JG, Pieters R, Versteeg R, Clustering of hypermethylated genes in neuroblastoma. GENE CHROMOSOME CANC 2003;38 (3):226-233 [PubMed]
Versteeg R, van Schaik BDC, van Batenburg MF, Roos M, Monajemi R, Caron H, Bussemaker HJ, van Kampen AHC, The human transcriptome map reveals extremes in gene density, intron length, GC content, and repeat pattern for domains of highly and weakly expressed genes. GENOME RES 2003;13 (9):1998-2004 [PubMed]
Godfried MB, Veenstra M, Valent A, Sluis Pv, Voûte PA, Versteeg R, Caron HN, Lack of interstitial chromosome 1p deletions in clinically-detected neuroblastoma. EUR J CANCER 2002;38 (11):1513-1519 [PubMed]
Godfried MB, Veenstra M, van Sluis P, Boon K, van Asperen R, Hermus MC, van Schaik BDC, Voûte TPA, Schwab M, Versteeg R, Caron HN, The N-myc and c-myc downstream pathways include the chromosome 17q genes nm23-H1 and nm23-H2. ONCOGENE 2002;21 (13):2097-2101 [PubMed]
van Noesel MM, van Bezouw S, Salomons GS, Voûte PA, Pieters R, Baylin SB, Herman JG, Versteeg R, Tumor-specific down-regulation of the tumor necrosis factor-related apoptosis-inducing ligand decoy receptors DcR1 and DcR2 is associated with dense promoter hypermethylation. CANCER RES 2002;62 (7):2157-2161 [PubMed]
van Roy N, Vandesompele J, Berx G, Staes K, van Gele M, de Smet E, de Paepe A, Laureys G, van der Drift P, Versteeg R, van Roy F, Speleman F, Localization of the 17q breakpoint of a constitutional 1;17 translocation in a patient with neuroblastoma within a 25-kb segment located between the ACCN1 and TLK2 genes and near the distal breakpoints of two microdeletions in neurofibromatosis type 1 patients. GENE CHROMOSOME CANC 2002;35 (2):113-120 [PubMed]
Boon K, Caron HN, van Asperen R, Valentijn L, Hermus MC, van Sluis P, Roobeek I, Weis I, Voûte PA, Schwab M, Versteeg R, N-myc enhances the expression of a large set of genes functioning in ribosome biogenesis and protein synthesis. EMBO J 2001;20 (6):1383-1393 [PubMed]
Caron H, Spieker N, Godfried M, Veenstra M, van Sluis P, de Kraker J, Voûte P, Versteeg R, Chromosome bands 1p35-36 contain two distinct neuroblastoma tumor suppressor loci, one of which is imprinted. GENE CHROMOSOME CANC 2001;30 (2):168-174 [PubMed]
Caron H, van Schaik B, van der Mee M, Baas F, Riggins G, van Sluis P, Hermus MC, van Asperen R, Boon K, Voûte PA, Heisterkamp S, van Kampen A, Versteeg R, The human transcriptome map: clustering of highly expressed genes in chromosomal domains. SCIENCE 2001;291 (5507):1289-1292 [PubMed]
Spieker N, Beitsma M, van Sluis P, Chan A, Caron H, Versteeg R, Three chromosomal rearrangements in neuroblastoma cluster within a 300-kb region on 1p36.1. GENE CHROMOSOME CANC 2001;31 (2):172-181 [PubMed]
Spieker N, van Sluis P, Beitsma M, Boon K, van Schaik BD, van Kampen AH, Caron H, Versteeg R, The MEIS1 oncogene is highly expressed in neuroblastoma and amplified in cell line IMR32. GENOMICS 2001;71 (2):214-221 [PubMed]
Spieker N, Beitsma M, van Sluis P, Roobeek I, den Dunnen JT, Speleman F, Caron H, Versteeg R, An integrated 5-Mb physical, genetic, and radiation hybrid map of a 1p36.1 region implicated in neuroblastoma pathogenesis. GENE CHROMOSOME CANC 2000;27 (2):143-152 [PubMed]
van Kampen AH, van Schaik BD, Pauws E, Michiels EM, Ruijter JM, Caron HN, Versteeg R, Heisterkamp SH, Leunissen JA, Baas F, van der Mee M, USAGE: a web-based approach towards the analysis of SAGE data. Serial Analysis of Gene Expression. BIOINFORMATICS 2000;16 (10):899-905 [PubMed]
van Limpt V, Chan A, Caron H, Sluis PV, Boon K, Hermus MC, Versteeg R, SAGE analysis of neuroblastoma reveals a high expression of the human homologue of the Drosophila Delta gene. MED PEDIATR ONCOL 2000;35 (6):554-558 [PubMed]
van der Drift P, Chan A, Zehetner G, Westerveld A, Versteeg R, Multiple MSP pseudogenes in a local repeat cluster on 1p36.2: An expanding genomic graveyard?. GENOMICS 1999;62 (1):74-81 [PubMed]
Wuyts W, Spieker N, van Roy N, de Boulle K, de Paepe A, Willems PJ, van Hul W, Versteeg R, Speleman F, Refined physical mapping and genomic structure of the EXTL1 gene. CYTOGENET CELL GENET 1999;86 (3-4):267-270 [PubMed]
van Gele M, van Roy N, Ronan SG, Messiaen L, Vandesompele J, Geerts ML, Naeyaert JM, Blennow E, Bar-Am I, Das Gupta TK, van der Drift P, Versteeg R, Leonard JH, Speleman F, Molecular analysis of 1p36 breakpoints in two Merkel cell carcinomas. GENE CHROMOSOME CANC 1998;23 (1):67-71 [PubMed]
van Gele M, van Roy N, Jauch A, Laureys G, Benoit Y, Schelfhout V, de Potter CR, Brock P, Uyttebroeck A, Sciot R, Schuuring E, Versteeg R, Speleman F, Sensitive and reliable detection of genomic imbalances in human neuroblastomas using comparative genomic hybridisation analysis. EUR J CANCER 1997;33 (12):1979-1982 [PubMed]
van Roy N, Jauch A, van Gele M, Laureys G, Versteeg R, de Paepe A, Cremer T, Speleman F, Comparative genomic hybridization analysis of human neuroblastomas: detection of distal 1p deletions and further molecular genetic characterization of neuroblastoma cell lines. CANCER GENET CYTOGEN 1997;97 (2):135-142 [PubMed]
van Roy N, Laureys G, van Gele M, Opdenakker G, Miura R, van der Drift P, Chan A, Versteeg R, Speleman F, Analysis of 1;17 translocation breakpoints in neuroblastoma: implications for mapping of neuroblastoma genes. EUR J CANCER 1997;33 (12):1974-1978 [PubMed]
Versteeg R, Aberrant methylation in cancer. AM J HUM GENET 1997;60 (4):751-754 [PubMed]
Caron HN, Voute PA, Versteeg R, Allelic loss of chromosome 1p in neuroblastoma - Reply. NEW ENGL J MED 1996;334 (24):1609
Caron H, van Sluis P, Buschman R, Pereira do Tanque R, Maes P, Beks L, de Kraker J, Voûte PA, Vergnaud G, Westerveld A, Slater R, Versteeg R, Allelic loss of the short arm of chromosome 4 in neuroblastoma suggests a novel tumour suppressor gene locus. HUM GENET 1996;97 (6):834-837 [PubMed]
Caron H, van Sluis P, de Kraker J, Bökkerink J, Egeler M, Laureys G, Slater R, Westerveld A, Voûte PA, Versteeg R, Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. NEW ENGL J MED 1996;334 (4):225-230 [PubMed]
Cheng NC, Beitsma M, Chan A, Op den Camp I, Westerveld A, Pronk J, Versteeg R, Lack of class I HLA expression in neuroblastoma is associated with high N-myc expression and hypomethylation due to loss of the MEMO-1 locus. ONCOGENE 1996;13 (8):1737-1744 [PubMed]
Cheng NC, Chan AJ, Beitsma MM, Speleman F, Westerveld A, Versteeg R, A human modifier of methylation for class I HLA genes (MEMO-1) maps to chromosomal bands 1p35-36.1. HUM MOL GENET 1996;5 (3):309-317 [PubMed]
Hofstra RM, Cheng NC, Hansen C, Stulp RP, Stelwagen T, Clausen N, Tommerup N, Caron H, Westerveld A, Versteeg R, Buys CH, No mutations found by RET mutation scanning in sporadic and hereditary neuroblastoma. HUM GENET 1996;97 (3):362-364 [PubMed]
Paul DR, Gawlik C, Versteeg R, Arps H, Kleeberg UR, Correlation between the expression of Ki67 and HLA-DR antigens in fotemustine-treated melanoma cell lines. ONKOLOGIE 1996;19 (4):334-336
Caron H, Peter M, van Sluis P, Speleman F, de Kraker J, Laureys G, Michon J, Brugières L, Voûte PA, Westerveld A, Slater R, Delattre O, Versteeg R, EVIDENCE FOR 2 TUMOR-SUPPRESSOR LOCI ON CHROMOSOMAL BANDS-1P35-36 INVOLVED IN NEUROBLASTOMA - ONE PROBABLY IMPRINTED, ANOTHER ASSOCIATED WITH N-MYC AMPLIFICATION. HUM MOL GENET 1995;4 (4):535-539 [PubMed]
Cheng NC, van Roy N, Chan A, Beitsma M, Westerveld A, Speleman F, Versteeg R, Deletion mapping in neuroblastoma cell lines suggests two distinct tumor suppressor genes in the 1p35-36 region, only one of which is associated with N-myc amplification. ONCOGENE 1995;10 (2):291-297 [PubMed]
Laureys G, Speleman F, Versteeg R, van der Drift P, Chan A, Leroy J, Francke U, Opdenakker G, van Roy N, Constitutional translocation t(1;17)(p36.31-p36.13;q11.2-q12.1) in a neuroblastoma patient. Establishment of somatic cell hybrids and identification of PND/A12M2 on chromosome 1 and NF1/SCYA7 on chromosome 17 as breakpoint flanking single copy markers. ONCOGENE 1995;10 (6):1087-1093 [PubMed]
Laureys G, Versteeg R, Speleman F, van der Drift P, Francke U, Opdenakker G, van Roy N, Characterisation of the chromosome breakpoints in a patient with a constitutional translocation t(1;17)(p36.31-p36.13;q11.2-q12) and neuroblastoma. EUR J CANCER 1995;31A (4):523-526 [PubMed]
van der Drift P, Chan A, Laureys G, van Roy N, Sickmann G, den Dunnen JT, Westerveld A, Speleman F, Versteeg R, Balanced translocation in a neuroblastoma patient disrupts a cluster of small nuclear RNA U1 and tRNA genes in chromosomal band 1p36. GENE CHROMOSOME CANC 1995;14 (1):35-42 [PubMed]
van Roy N, Cheng NC, Laureys G, Opdenakker G, Versteeg R, Speleman F, Molecular cytogenetic analysis of 1;17 translocations in neuroblastoma. EUR J CANCER 1995;31A (4):530-535 [PubMed]
van Roy N, Forus A, Myklebost O, Cheng NC, Versteeg R, Speleman F, Identification of two distinct chromosome 12-derived amplification units in neuroblastoma cell line NGP. CANCER GENET CYTOGEN 1995;82 (2):151-154 [PubMed]
Versteeg R, Caron H, Cheng NC, van der Drift P, Slater R, Westerveld A, Voûte PA, Delattre O, Laureys G, van Roy N, 1p36: every subband a suppressor?. EUR J CANCER 1995;31A (4):538-541 [PubMed]
Caron H, van Sluis P, van Roy N, de Kraker J, Speleman F, Voûte PA, Westerveld A, Slater R, Versteeg R, Recurrent 1;17 translocations in human neuroblastoma reveal nonhomologous mitotic recombination during the S/G2 phase as a novel mechanism for loss of heterozygosity. AM J HUM GENET 1994;55 (2):341-347 [PubMed]
van der Drift P, Chan A, van Roy N, Laureys G, Westerveld A, Speleman F, Versteeg R, A multimegabase cluster of snRNA and tRNA genes on chromosome 1p36 harbours an adenovirus/SV40 hybrid virus integration site. HUM MOL GENET 1994;3 (12):2131-2136 [PubMed]
van Roy N, Laureys G, Cheng NC, Willem P, Opdenakker G, Versteeg R, Speleman F, 1;17 translocations and other chromosome 17 rearrangements in human primary neuroblastoma tumors and cell lines. GENE CHROMOSOME CANC 1994;10 (2):103-114 [PubMed]
Caron H, van Sluis P, van Hoeve M, de Kraker J, Bras J, Slater R, Mannens M, Voûte PA, Westerveld A, Versteeg R, Allelic loss of chromosome 1p36 in neuroblastoma is of preferential maternal origin and correlates with N-myc amplification [Correction]. NAT GENET 1993;4 (4):431-431
Caron H, van Sluis P, van Hoeve M, de Kraker J, Bras J, Slater R, Mannens M, Voûte PA, Westerveld A, Versteeg R, Allelic loss of chromosome 1p36 in neuroblastoma is of preferential maternal origin and correlates with N-myc amplification. NAT GENET 1993;4 (2):187-190 [PubMed]
van Roy N, Laureys G, Versteeg R, Opdenakker G, Speleman F, High-resolution fluorescence mapping of 46 DNA markers to the short arm of human chromosome 1. GENOMICS 1993;18 (1):71-78 [PubMed]
Boschman GA, Rens W, Manders EM, Slater RM, Versteeg R, Aten JA, Detection of recurrent chromosome abnormalities in Ewing's sarcoma and peripheral neuroectodermal tumor cells using bivariate flow karyotyping. GENE CHROMOSOME CANC 1992;5 (4):375-384 [PubMed]
Versteeg R, CORRECTION. IMMUNOL TODAY 1992;13 (10):426
Versteeg R, NK cells and T cells: mirror images?. IMMUNOL TODAY 1992;13 (7):244-247 [PubMed]
van 't Veer LJ, Burgering BM, Versteeg R, Boot AJ, Ruiter DJ, Osanto S, Schrier PI, Bos JL, N-ras mutations in human cutaneous melanoma from sun-exposed body sites. MOL CELL BIOL 1989;9 (7):3114-3116 [PubMed]
Versteeg R, Krüse-Wolters KM, Plomp AC, van Leeuwen A, Stam NJ, Ploegh HL, Ruiter DJ, Schrier PI, Suppression of class I human histocompatibility leukocyte antigen by c-myc is locus specific. J EXP MED 1989;170 (3):621-635 [PubMed]
Versteeg R, Peltenburg LT, Plomp AC, Schrier PI, High expression of the c-myc oncogene renders melanoma cells prone to lysis by natural killer cells. J IMMUNOL 1989;143 (12):4331-4337 [PubMed]
Versteeg R, NOORDERMEER IA, Krüse-Wolters M, Ruiter DJ, Schrier PI, c-myc down-regulates class I HLA expression in human melanomas. EMBO J 1988;7 (4):1023-1029 [PubMed]
KONINGS A, HUPKES P, Versteeg R, Grosveld G, Reuser A, Galjaard H, Cloning a cDNA for the lysosomal alpha-glucosidase. BIOCHEM BIOPH RES CO 1984;119 (1):252-258 [PubMed]
van der Avoort HG, Teertstra R, Versteeg R, Weisbeek PJ, GENES AND REGULATORY SEQUENCES OF BACTERIOPHAGE-PHI-X174. BIOCHIM BIOPHYS ACTA 1983;741 (1):94-102 [PubMed]
Key publications

Molenaar JJ, Koster J, Zwijnenburg DA, van Sluis P, Valentijn LJ, van der Ploeg I, Hamdi M, van Nes J, Westerman BA, van Arkel J, Ebus ME, Haneveld F, Lakeman A, Schild L, Molenaar P, Stroeken P, van Noesel MM, Ora I, Santo EE, Caron HN, Westerhout EM, Versteeg R, Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. NATURE 2012;483 (7391):589-U107 [PubMed]
Valentijn LJ, Koster J, Zwijnenburg DA, Hasselt NE, van Sluis P, Volckmann R, van Noesel MM, George RE, Tytgat GAM, Molenaar JJ, Versteeg R, TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors. NAT GENET 2015;47 (12):1411-+ [PubMed]
Eleveld TF, Oldridge DA, Bernard V, Koster J, Daage LC, Diskin SJ, Schild L, Bentahar NB, Bellini A, Chicard M, Lapouble E, Combaret V, Legoix-Né P, Michon J, Pugh TJ, Hart LS, Rader J, Attiyeh EF, Wei JS, Zhang S, Naranjo A, Gastier-Foster JM, Hogarty MD, Asgharzadeh S, Smith MA, Guidry Auvil JM, Watkins TBK, Zwijnenburg DA, Ebus ME, van Sluis P, Hakkert A, van Wezel E, van der Schoot CE, Westerhout EM, Schulte JH, Tytgat GA, Dolman MEM, Janoueix-Lerosey I, Gerhard DS, Caron HN, Delattre O, Khan J, Versteeg R, Schleiermacher G, Molenaar JJ, Maris JM, Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. NAT GENET 2015;47 (8):864-871 [PubMed]
Molenaar JJ, Domingo-Fernández R, Ebus ME, Lindner S, Koster J, Drabek K, Mestdagh P, van Sluis P, Valentijn LJ, van Nes J, Broekmans M, Haneveld F, Volckmann R, Bray I, Heukamp L, Sprüssel A, Thor T, Kieckbusch K, Klein-Hitpass L, Fischer M, Vandesompele J, Schramm A, van Noesel MM, Varesio L, Speleman F, Eggert A, Stallings RL, Caron HN, Versteeg R, Schulte JH, LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. NAT GENET 2012;44 (11):1199-1206 [PubMed]
Versteeg R, CANCER Tumours outside the mutation box. NATURE 2014;506 (7489):438-439 [PubMed]


All Publications

Research programmes

Regulatory networks in cancer

The research program focuses on the elucidation of the regulatory networks underlying pathogenesis of the childhood tumors neuroblastoma, medulloblastoma and rhabdomyosarcoma. Affymetrix profiling was performed on large series of these tumors. Genes with a role in these tumors are systematically switched on or switched off in cell lines by inducible cDNA or siRNA expression (Tet-on system). RNA from time-courses of these cell lines was analyzed by Affymetrix expression arrays, usually in triplo and of different clones. Downstream pathways of about 15 genes were analyzed in this way. Elaborate bioinformatics programs were generated to identify downstream networks of the manipulated genes and to relate these data to the expression patterns observed in the tumor series. As each of the manipulated genes (like MYCN, NOTCH, EZH2, MSX1, CDK2) appear to regulate expression of hundreds of downstream genes, the emerging networks appear to be complex. The networks are further analyzed by silencing of transcription factors and other key genes in the networks. This requires an increase in the number of gene manipulations. For this purpose we have started to silence gene expression by lentivirally encoded siRNAs (TRC library). Over 15 genes were efficiently silenced this way and their downstream pathways are currently analyzed by microarrays. 

 

Theme: Oncology

Faculty
Prof. dr. R. Versteeg
Dr. J. Koster
Dr. L.J. Valentijn PhD

Postdocs
Dr. M. Hamdi PhD
Dr. W.J. van Nes
Dr. E.M. Westerhout

PhD Students
M.C. Commandeur MSc
T.F. Eleveld MSc
Drs. T.J. van Groningen
A. Hakkert
M.C. Lecca
Drs. N.E. Nowakowska

Others
Drs. P. Molenaar
Ing. D. Zwijnenburg

Prof. dr. H.N. Caron MD PhD (Paediatric Oncology; biology and clinical)

Other research related activities
  • None reported
Current research funding
  • AMC
  • Europese Unie
  • KWF Kankerbestrijding
  • Stichting Villa Joep
  • ZonMw